H. Lundbeck A/S
HLUN-A.CO
Get informed when a big investor buys or sells
+ FollowMarket Cap$41.37B
Close$
Share Statistics
| Market cap | $41.37 Billion |
|---|---|
| Enterprise Value | $48.60 Billion |
| Dividend Yield | $1.15 (2.21%) |
| Earnings per Share | $3.22 |
| Beta | 0.24 |
| Outstanding Shares | 989,655,172 |
Return
| Return on Equity | 14.44% |
|---|---|
| Return on Assets | 7.36% |
| Return on Invested Capital | 13.52% |
Valuation & Multiples
| P/E Ratio | 13.32 |
|---|---|
| PEG | 70.67 |
| Price to Sales | 1.95 |
| Price to Book Ratio | 1.81 |
| Enterprise Value to Revenue | 1.9 |
| Enterprise Value to EBIT | 8.29 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.35 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$6.40 B
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$6.36 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About H. Lundbeck A/S
5,214 employees
CEO: Charl van Zyl H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily sp...